BR112017019856A2 - compositions and methods for treating acute myeloid leukemia and myelodysplastic syndromes - Google Patents

compositions and methods for treating acute myeloid leukemia and myelodysplastic syndromes

Info

Publication number
BR112017019856A2
BR112017019856A2 BR112017019856A BR112017019856A BR112017019856A2 BR 112017019856 A2 BR112017019856 A2 BR 112017019856A2 BR 112017019856 A BR112017019856 A BR 112017019856A BR 112017019856 A BR112017019856 A BR 112017019856A BR 112017019856 A2 BR112017019856 A2 BR 112017019856A2
Authority
BR
Brazil
Prior art keywords
myeloid
lymphoid
antibody
treatment
methods
Prior art date
Application number
BR112017019856A
Other languages
Portuguese (pt)
Inventor
Y Park Christopher
Tavakkoli Montreh
Shiu-Sah Chung Stephen
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112017019856A2 publication Critical patent/BR112017019856A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

são fornecidos composições e métodos para o tratamento de condições hematológicas, em particular malignidades hematopoiéticas e linfoides incluindo leucemias mielogênicas agudas cd99+ (aml), síndromes mielodisplásicas (mds) e neoplasmas de células t, que compreendem um ou mais anticorpos que (a) se ligam ao domínio extracelular de cd99, (b) se ligam ao cd99 expresso na superfície das células malignas mieloides ou linfoides, (c) promovem a adição de cap/agrupamento/agregação do cd99 expresso na superfície das células malignas mieloides ou linfoides e (d) induzem a apoptose em e consequente à citotoxicidade de células malignas mieloides ou linfoides cd99+ ligadas ao anticorpo. os métodos divulgados incluem métodos para identificação de pacientes que sofrem de uma malignidade hematopoiética ou linfoide que são suscetíveis ao tratamento com um anticorpo anti-cd99 através da detecção da expressão elevada de cd99 em uma amostra de tecido ou uma célula maligna mieloide ou linfoide de um paciente e para o tratamento de um paciente que sofre de uma malignidade hematopoiética ou linfoide que exibe expressão elevada do gene cd99 e ou da proteína na superfície celular através da administração de uma composição que compreende um anticorpo anti-cd99, isoladamente ou em combinação com um ou mais componentes adicionais tais como um agente de mobilização, um agente de bloqueio de transmigração e um agente quimioterapêutico, tal como daunorrubicina, idarrubicina, citarabina, 5-azacitidina e decitabina.Compositions and methods are provided for the treatment of hematological conditions, in particular hematopoietic malignancies and lymphoids including cd99 + acute myelogenic leukemias (aml), myelodysplastic syndromes (mds) and t-cell neoplasms, which comprise one or more antibodies that bind (a) to the extracellular domain of cd99, (b) bind to cd99 expressed on the surface of myeloid or lymphoid malignant cells, (c) promote the addition of cd99 cap / pool / aggregation expressed on the surface of myeloid or lymphoid malignant cells and (d) induce apoptosis in and consequent to cytotoxicity of antibody-linked myeloid or cd99 + lymphoid malignant cells. The disclosed methods include methods for identifying patients suffering from a hematopoietic or lymphoid malignancy who are susceptible to treatment with an anti-cd99 antibody by detecting elevated cd99 expression in a tissue sample or a myeloid or lymphoid malignant cell of a patient and for the treatment of a patient suffering from a hematopoietic or lymphoid malignancy that exhibits elevated cd99 gene and / or protein expression on the cell surface by administering a composition comprising an anti-cd99 antibody, either alone or in combination with a or more additional components such as a mobilizing agent, a transmigration blocking agent and a chemotherapeutic agent such as daunorubicin, idarubicin, cytarabine, 5-azacytidine and decitabine.

BR112017019856A 2015-03-18 2016-03-18 compositions and methods for treating acute myeloid leukemia and myelodysplastic syndromes BR112017019856A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135119P 2015-03-18 2015-03-18
PCT/US2016/023303 WO2016149682A2 (en) 2015-03-18 2016-03-18 Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies

Publications (1)

Publication Number Publication Date
BR112017019856A2 true BR112017019856A2 (en) 2018-05-29

Family

ID=56919925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019856A BR112017019856A2 (en) 2015-03-18 2016-03-18 compositions and methods for treating acute myeloid leukemia and myelodysplastic syndromes

Country Status (9)

Country Link
EP (1) EP3271399A4 (en)
JP (1) JP2018511311A (en)
KR (1) KR20170136535A (en)
CN (1) CN107614531A (en)
AU (1) AU2016232719A1 (en)
BR (1) BR112017019856A2 (en)
CA (1) CA2980038A1 (en)
MX (1) MX2017011882A (en)
WO (1) WO2016149682A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136419A2 (en) * 2018-01-08 2019-07-11 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods for targeting cd99-expressing cancers
IT201800005991A1 (en) * 2018-06-04 2019-12-04 Antibody complex and derivative uses
WO2019234580A1 (en) * 2018-06-04 2019-12-12 Diatheva S.R.L. Anti-cd99 diabody or igg antibody and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871517A (en) * 2002-02-19 2006-11-29 免疫公司 Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2006024169A1 (en) * 2004-09-01 2006-03-09 Hemax Genome Inc. Genes of the pseudoautosomal region 1 and their use in the diagnosis, treatment and prevention of autoimmune diseases
US8088382B2 (en) * 2005-07-05 2012-01-03 Cornell Research Foundation, Inc. Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
US20110230372A1 (en) * 2008-11-14 2011-09-22 Stc Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia
SI2477648T1 (en) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
US20150071987A1 (en) * 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2015069935A1 (en) * 2013-11-06 2015-05-14 Memorial Sloan-Kettering Cancer Center Compositions and methods for the treatment of acute myeloid leukemias and myelodysplastic syndromes

Also Published As

Publication number Publication date
WO2016149682A2 (en) 2016-09-22
MX2017011882A (en) 2018-04-20
CN107614531A (en) 2018-01-19
AU2016232719A1 (en) 2017-10-12
JP2018511311A (en) 2018-04-26
KR20170136535A (en) 2017-12-11
WO2016149682A3 (en) 2017-01-26
CA2980038A1 (en) 2016-09-22
EP3271399A4 (en) 2019-03-20
EP3271399A2 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
CR11687A (en) COMBINATION THERAPY OF AN ANTI-CD20 TYPE II ANTIBODY WITH INCREASED ANTIBODY CELLULAR CYTOTOXICITY (CCDA)
BR112018067977A2 (en) cd20 immunotherapy compositions and methods
BR112015026095A8 (en) method of using tumor-responsive biomarkers, method for selecting at least one anti-tumor drug, composition comprising an anti-tumor drug, combination to control the dosage of an anti-tumor drug, use of tumor-responsive biomarkers
BR112017019856A2 (en) compositions and methods for treating acute myeloid leukemia and myelodysplastic syndromes
EA201692200A1 (en) COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE STRUCTURE AND ITS APPLICATION
AR065589A1 (en) PREDICTION OF RESPONSE TO A HER INHIBITOR
RU2016122232A (en) COMBINED THERAPY BASED ON AN ANTIBODY TO CD20 AND VTK INHIBITOR
BR112015016681A8 (en) use of nanoparticles comprising paclitaxel and an albumin, kit, drug, composition and unit dosage form for the treatment of pancreatic cancer
AR049305A1 (en) METHOD FOR TREATING CANCER RESISTANT TO THE PLATINUM WITH A HER2 ANTIBODY AND A CHEMOTHERAPEUTIC AGENT: GEMCITABINA
BR112015029386A2 (en) use of eribulin and lenvatinib as combination therapy for cancer treatment
AR089978A1 (en) TRANSLOCATIONS OF R-SPONDIN AND ITS METHODS OF USE, TREATMENT METHOD, ANTAGONISTS
UY33700A (en) ? PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS ?.
CL2013003455A1 (en) Use of benzene-derived sglt-2 inhibitor compounds substituted by glucopyranosyl to prevent, slow progression, delay or treat a metabolic disorder in a patient with a neuroleptic agent; use of the combination of the sglt2 inhibitor with a neuroleptic; and pharmaceutical composition of the combination.
BR112022009139A2 (en) IMMUNOSTIMULATING BACTERIA DISPENSING PLATFORMS AND THEIR USE FOR DISPENSING THERAPEUTIC PRODUCTS
BR112015025025A2 (en) therapeutic compositions and uses thereof
BR112013031892A2 (en) anti-psgl-1 antibodies and their use
BR112015022181A2 (en) proteins of the modified mullerian inhibiting substance (mis) and their uses for the treatment of the disease (s)
BR112018076639A2 (en) combination chemotherapies
BR112021025375A2 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for the treatment of leukemia or myelodysplastic syndrome
AR095555A1 (en) THERAPEUTIC USE OF ANTIBODIES DIRECTED TO THE HEPATOCITE GROWTH FACTOR (HGF)
BR112015024621A8 (en) unit dose uses of colony forming units of c. novyi, a pharmaceutical composition comprising said unit dose, kit for treating or attenuating an effect of a solid tumor present in a human and unit dose of c. novyi
MX2020004910A (en) Compositions and methods for the depletion of cd5+ cells.
BR112022006476A2 (en) OLIGONUCLEOTIDES WITH NUCLEOSID ANALOGS
BR112018002520A2 (en) TLR4 AGONISTS AND COMPOSITIONS OF THE SAME AND ITS USE IN CANCER TREATMENT
CL2020003306A1 (en) Bifunctional compositions for the treatment of cancer.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired